Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden.

Specifically, 69.8%, 67.7%, and 69.0% of patients prescribed adjustable-dose BUD/FORM maintenance, fixed-dose BUD/FORM maintenance, and intermittent BUD/FORM, respectively, did not claim SABA during follow-up (Table 1). Adjustable-dose BUD/FORM maintenance: physician-indicated temporary titration of BUD/FORM maintenance therapy to a maximum daily dose in the event of deteriorating asthma control plus an as-needed SABA reliever. [Extracted from the article]